This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use



2016 BioInfect Conference

Location: Alderley Park Conference Centre, Alderley Park, Cheshire

A major 1-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.

Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective. When the microorganisms become resistant to most antimicrobials they are often referred to as “superbugs”. This is a major concern because a resistant infection may kill, can spread to others, and imposes huge costs to individuals and society.

Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. It is an increasingly serious threat to global public health that requires action across all government sectors and society.

Conference Programme


Coffee & Registration


Welcome to the Conference

Geoff Davison, CEO, Bionow


Introduction from the Conference Chair

Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence at Informa


A Patients View

Derek Butler, MRSA Action UK


Keynote Address

Lord Jim O'Neill


State of the Nation
What are the major challenges?
What progress has been made?
Which models might work?
Which models won't

Session Chair: Jo Pisani, Partner, PwC

Neil Murray, CEO, Redx Pharma
Lloyd Czaplewski, Director, Abgentis / Project Manager, ANTRUK
Joe Larson, Deputy Director, BARDA
Lynn Marks, Senior Vice President, GSK
John Fitzgerald, Secretary General, RUMA 


Coffee, Networking & Exhibition


Clinical Aspects

Session Chair : Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence at Informa

Helga Rubasamen-Schaeff, Chair, AiCuris 
Harpal Dhillon, Medical Advisor - Antibiotics, MSD UK
Lynn Marks, Senior Vice President, GSK
Seamus O'Brien, Executive Director, Antibiotics Business Unit, AstraZeneca


Lunch, Networking & Exhibition


Keynote Address

Joe Larson, CARB-X & BARDA
Pete Jackson, AMR Centre


Making Progress - New technologies to advance the antibiotic pipeline
A series of presentations highlighting significant recent developments

Session Chair: David Williams, CEO, Discuva

Fiona Marston, CEO, Absynth Biologics
Douglas Fraser-Pitt, Principle Scientist, NovaBiotics
Tim Paget, Sunderland University


Animal Health
How do we meet the needs of both human and animal health?
What developments are driving progress in this area?
How can we reduce the disease challenge?

Session Chair: John Fitzgerald, Secretary General, RUMA

Niall Morton, Wallace Vets
Rob Smith, Professor, University of Liverpool
Tony Simon, Director, Zoetis
Donal Murphy, NOAH


Coffee, Networking & Exhibition


How diagnostic tests are critical to the global AMR challenge
How can new rapid diagnostics support more accurate prescribing of antibiotics?
How do health systems use diagnostics today?
What are the challenges in developing and adopting rapid diagnostic tests?
What funding models can be envisaged which can enable the development of rapid diagnostics?

Session Chair: Jonathan O'Halloran, Co-Founder, QuantuMDx

Simon Travers, Managing Director, Hyrax Biosciences
Neil Butler, CEO, Spectromics
Sanjeev Krishna, Professor of Molecular Parasitology, St Georges Hospital
Daniel Berman, Lead Longitude Prize, Nesta


Closing Remarks

Steve Bates, CEO, BIA

You can view a snapshot of the 2015 BioInfect Conference with interviews from speakers including Lord Jim O'Neill via the video link on this page.

Delegate Fees

Premium Member - £125.00 + VAT
Member - £150.00 + VAT
Non-Member - £250.00 + VAT

Exhibition and Sponsorship
For details of the exhibition and sponsorship opportunities available, please contact Helen Williams on 07714 16802007714 168020 or at

> Register here